Human immunodeficiency virus type 1 polymerase polyprotein conserved epitopes (HIV-1 Pol conserved epitopes)

HIV-1 Pol conserved epitopes are highly stable amino acid sequences within the HIV-1 polymerase (Pol) polyprotein, which encompasses the essential viral enzymes protease, reverse transcriptase, and integrase [UniProt P03366]. These regions are characterized by high sequence conservation across diverse HIV-1 clades because mutations within them typically incur a significant fitness cost, impairing the virus's ability to replicate [Mothe et al., 2015]. As a result, these epitopes are primary targets for T-cell-based vaccines and immunotherapies designed to elicit broad and durable cellular immune responses [Hanke, 2019]. By directing the immune system toward these vulnerable segments, therapeutic strategies aim to prevent viral escape and achieve better control of the viral reservoir in HIV-infected individuals [ClinicalTrials.gov, NCT04388618]. These epitopes are typically delivered via viral vectors, such as Modified Vaccinia Ankara (MVA) or Adenovirus, or as DNA immunogens to stimulate CD8+ cytotoxic T-lymphocytes [Bailon et al., 2020]. While standard antiretroviral therapy (ART) targets the enzymatic activity of Pol, epitope-based therapies focus on the immunological recognition of these regions to achieve a functional cure.

Other names

HIV-1 Pol polyproteinHIV-1 Pol-derived T-cell epitopesConserved HIV-1 Pol regionsHIV-1 Pol highly conserved regions (HCRs)HIV-1 Pol antigens

Vaccines targeting these epitopes function by presenting highly conserved viral peptides via Major Histocompatibility Complex (MHC) Class I and II molecules to prime and expand HIV-specific CD8+ and CD4+ T-cells [Mothe et al., 2015]. These T-cells then identify and lyse infected cells, suppressing viral replication and preventing mutational escape by focusing the immune response on regions where mutations cause high fitness costs to the virus [Hanke, 2019].